XML 69 R54.htm IDEA: XBRL DOCUMENT
v3.8.0.1

BUSINESS CONCENTRATIONS (Details Narrative) - USD ($) | 3 Months Ended | 12 Months Ended
--- | --- | ---
Dec. 31, 2017 | Sep. 30, 2017 | Jun. 30, 2017 | Mar. 31, 2017 | Dec. 31, 2016 | Sep. 30, 2016 | Jun. 30, 2016 | Mar. 31, 2016 | Dec. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015
Concentration Risk [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues | $ 4,125,000 | $ 4,418,000 | $ 4,250,000 | $ 3,985,000 | $ 4,487,000 | $ 5,536,000 | $ 4,403,000 | $ 4,930,000 | $ 16,777,713 | $ 19,356,450 | $ 20,142,898
Supplier Concentration Risk [Member] |  |  |  |  |  |  |  |  |  |  |
Concentration Risk [Line Items] |  |  |  |  |  |  |  |  |  |  |
Concentration Risk |  |  |  |  |  |  |  |  | 100.00% | 98.00% | 60.00%
Customer Concentration Risk [Member] | Sales Revenue [Member] | AmerisourceBergen [Member] |  |  |  |  |  |  |  |  |  |  |
Concentration Risk [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | $ 2,667,000 |  |
Customer Concentration Risk [Member] | Sales Revenue [Member] | McKesson Corporation [Member] |  |  |  |  |  |  |  |  |  |  |
Concentration Risk [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 1,959,000 |  |
Customer Concentration Risk [Member] | Sales Revenue [Member] | Cardinal Health [Member] |  |  |  |  |  |  |  |  |  |  |
Concentration Risk [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | 2,559,000 |  |
Customer Concentration Risk [Member] | Sales Revenue [Member] | Pharmacy Innovations PA [Member] |  |  |  |  |  |  |  |  |  |  |
Concentration Risk [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  | $ 2,715,000 | $ 2,040,000 |
Customer Concentration Risk [Member] | Sales Revenue [Member] | Woodstock Pharmaceutical and Compounding [Member] |  |  |  |  |  |  |  |  |  |  |
Concentration Risk [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  |  | 2,247,000 | $ 8,848,000
Customer Concentration Risk [Member] | Sales Revenue [Member] | Medical Center Pharmacy [Member] |  |  |  |  |  |  |  |  |  |  |
Concentration Risk [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  |  | $ 3,700,000 |
Customer Concentration Risk [Member] | Sales Revenue [Member] | Due West Pharmacy [Member] |  |  |  |  |  |  |  |  |  |  |
Concentration Risk [Line Items] |  |  |  |  |  |  |  |  |  |  |
Revenues |  |  |  |  |  |  |  |  |  |  | $ 4,843,000
Customer Concentration Risk [Member] | Sales Revenue [Member] | Minimum [Member] |  |  |  |  |  |  |  |  |  |  |
Concentration Risk [Line Items] |  |  |  |  |  |  |  |  |  |  |
Concentration Risk |  |  |  |  |  |  |  |  | 10.00% |  |
Customer Concentration Risk [Member] | Sales Revenue [Member] | Four Customers [Member] |  |  |  |  |  |  |  |  |  |  |
Concentration Risk [Line Items] |  |  |  |  |  |  |  |  |  |  |
Concentration Risk |  |  |  |  |  |  |  |  | 59.00% |  |
Customer Concentration Risk [Member] | Sales Revenue [Member] | Three Customers [Member] |  |  |  |  |  |  |  |  |  |  |
Concentration Risk [Line Items] |  |  |  |  |  |  |  |  |  |  |
Concentration Risk |  |  |  |  |  |  |  |  |  | 41.00% |
Customer Concentration Risk [Member] | Sales Revenue [Member] | Two Customers [Member] |  |  |  |  |  |  |  |  |  |  |
Concentration Risk [Line Items] |  |  |  |  |  |  |  |  |  |  |
Concentration Risk |  |  |  |  |  |  |  |  |  |  | 67.00%

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_ConcentrationRiskLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -URI http://asc.fasb.org/extlink&oid=84177426&loc=d3e6351-108592 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=77997519&loc=d3e13531-108611 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=84177426&loc=d3e6404-108592 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=77997519&loc=d3e13537-108611 + Details
Name: | us-gaap_ConcentrationRiskPercentage1
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688 + Details
Name: | us-gaap_SalesRevenueNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_ConcentrationRiskByTypeAxis=us-gaap_SupplierConcentrationRiskMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=txmd_AmerisourceBergenMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=txmd_McKessonCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=txmd_CardinalHealthMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=txmd_PharmacyInnovationsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=txmd_WoodstockPharmaceuticalAndCompoundingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=txmd_MedicalCenterPharmacyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=txmd_DueWestPharmacyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MajorCustomersAxis=txmd_FourCustomersMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MajorCustomersAxis=txmd_ThreeCustomersMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MajorCustomersAxis=txmd_TwoCustomersMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |